Page 84 - SAHCS HIVMed Journal Vol 20 No 1 2019

Page 4 of 4 Case Report

References 6. Rossouw TM, Hitchcock S, Botes M. The end of the line? A case of drug resistance
to third-line antiretroviral therapy. South Afr J HIV Med. 2016;17(1):3–5. https://
doi.org/10.4102/sajhivmed.v17i1.454
1. Tang MW, Shafer RW. HIV-1 antiretroviral resistance: Scientific principles and
clinical applications. Drugs. 2012;72(9):1–25. https://doi.org/10.2165/11633630- 7. Barnett W, Patten G, Kerschberger B, et al. Original article: Perceived adherence
000000000-00000 barriers among patients failing second-line antiretroviral therapy in Khayelitsha,
2. Hamers RL, Rinke de Wit TF, Holmes CB. HIV drug resistance in low-income and South Africa. South Afr J HIV Med. 2013;14(4):170–176. https://doi.org/10.7196/
middle-income countries. Lancet HIV. 2018;5(10):e588–e596. https://doi.org/ SAJHIVMED.981
10.1016/S2352-3018(18)30173-5 8. Blanco JL, Marcelin A-G, Katlama C, Martinez E. Dolutegravir resistance mutations.
3. Wallis CL, Godfrey C, Fitzgibbon JE, Mellors JW. Factors influencing the emergence of Curr Opin Infect Dis. 2018;31(3):237–245. https://doi.org/10.1097/QCO.000000
human immunodeficiency virus drug resistance in low-and middle-income countries. 0000000453
J Inf Dis. 2017;216(Suppl 9):S851–S856. https://doi.org/10.1093/inf dis/jix409
9. Anstett K, Brenner B, Mesplede T, Wainberg MA. HIV drug resistance against
4. National Medicine and Therapeutics Policy Advisory Committee; The AIDS and TB strand transfer integrase inhibitors. Retrovirology. 2017;14(1):1–16. https://doi.
Directorate Ministry of Health and Child Care. Guidelines for antiretroviral therapy
for the prevention and treatment of HIV in Zimbabwe. 2016; p. 1–88. org/10.1186/s12977-017-0360-7
5. Seatla KK, Avalos A, Moyo S, et al. Four class drug resistant HIV-1 subtype C in a treatment 10. Dow DE, Bartlett JA. Dolutegravir, the second-generation of Integrase Strand Transfer
experienced individual on dolutegravir based antiretroviral therapy in Botswana. AIDS. Inhibitors (INSTIs) for the treatment of HIV. Infect Dis Ther. 2014;3(2):83–102.
2018;32(13):1899–1902. https://doi.org/10.1097/QAD.0000000 000001920 https://doi.org/10.1007/s40121-014-0029-7

http://www.sajhivmed.org.za 77 Open Access